![Idenix Pharmaceuticals logo](/news-release/logo/292339/0/292339.jpg?lastModified=12%2F10%2F2016%2003%3A15%3A26&size=2)
Idenix Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic HCV NS5A Inhibitor, at EASL Meeting
24 avr. 2013 08h00 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., April 24, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of...